Bicycle Therapeutics plc (50BA) - Total Liabilities
Based on the latest financial reports, Bicycle Therapeutics plc (50BA) has total liabilities worth €98.08 Million EUR (≈ $114.66 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 50BA net asset momentum to track the company's year-over-year net asset growth rate.
Bicycle Therapeutics plc - Total Liabilities Trend (2018–2025)
This chart illustrates how Bicycle Therapeutics plc's total liabilities have evolved over time, based on quarterly financial data. See Bicycle Therapeutics plc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Bicycle Therapeutics plc Competitors by Total Liabilities
The table below lists competitors of Bicycle Therapeutics plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Genova Property Group AB
ST:GPG
|
Sweden | Skr8.45 Billion |
|
HomeToGo SE
F:HTG
|
Germany | €350.56 Million |
|
Icelandic Salmon As
OL:ISLAX
|
Norway | Nkr153.36 Million |
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
USA | $29.51 Million |
|
Allpark Empreendimentos Participações e Serviços S.A
SA:ALPK3
|
Brazil | R$2.23 Billion |
|
Suryoday Small Finance Bank Limited
NSE:SURYODAY
|
India | Rs150.10 Billion |
|
Songwon Industrial
KO:004430
|
Korea | ₩432.87 Billion |
|
Translational Development Acquisition Corp. Ordinary Shares
NASDAQ:TDAC
|
USA | $6.46 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Bicycle Therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 50BA company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bicycle Therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bicycle Therapeutics plc (2018–2025)
The table below shows the annual total liabilities of Bicycle Therapeutics plc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €107.62 Million ≈ $125.82 Million |
-34.30% |
| 2024-12-31 | €163.81 Million ≈ $191.51 Million |
-27.01% |
| 2023-12-31 | €224.41 Million ≈ $262.36 Million |
+60.49% |
| 2022-12-31 | €139.83 Million ≈ $163.47 Million |
+4.71% |
| 2021-12-31 | €133.54 Million ≈ $156.12 Million |
+103.28% |
| 2020-12-31 | €65.69 Million ≈ $76.80 Million |
+286.51% |
| 2019-12-31 | €17.00 Million ≈ $19.87 Million |
-88.78% |
| 2018-12-31 | €151.45 Million ≈ $177.06 Million |
-- |
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide … Read more